665 related articles for article (PubMed ID: 12727833)
1. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
2. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells.
Carbonneil C; Saidi H; Donkova-Petrini V; Weiss L
Int Immunol; 2004 Jul; 16(7):1037-52. PubMed ID: 15184347
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. Activation of purified allogeneic CD4(+) T cells by rat bone marrow-derived dendritic cells induces concurrent secretion of IFN-gamma, IL-4, and IL-10.
Janelidze S; Enell K; Visse E; Darabi A; Salford LG; Siesjö P
Immunol Lett; 2005 Nov; 101(2):193-201. PubMed ID: 16002150
[TBL] [Abstract][Full Text] [Related]
6. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production.
Kronin V; Winkel K; Süss G; Kelso A; Heath W; Kirberg J; von Boehmer H; Shortman K
J Immunol; 1996 Nov; 157(9):3819-27. PubMed ID: 8892611
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site.
Halak BK; Maguire HC; Lattime EC
Cancer Res; 1999 Feb; 59(4):911-7. PubMed ID: 10029084
[TBL] [Abstract][Full Text] [Related]
8. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
9. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo.
Mejri N; Brossard M
Int Immunol; 2007 Apr; 19(4):535-43. PubMed ID: 17344202
[TBL] [Abstract][Full Text] [Related]
10. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
11. Differential capacity of CD8+ alpha or CD8- alpha dendritic cell subsets to prime for eosinophilic airway inflammation in the T-helper type 2-prone milieu of the lung.
Hammad H; de Vries VC; Maldonado-Lopez R; Moser M; Maliszewski C; Hoogsteden HC; Lambrecht BN
Clin Exp Allergy; 2004 Dec; 34(12):1834-40. PubMed ID: 15663556
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase 3 activity during development of bone marrow-derived dendritic cells (DCs) essential for the DC function to induce T helper 2 polarization.
Ono T; Yanagawa Y; Iwabuchi K; Nonomura K; Onoé K
Immunology; 2007 Oct; 122(2):189-98. PubMed ID: 17490435
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/interleukin-23-deficient mice.
Bastos KR; de Deus Vieira de Moraes L; Zago CA; Marinho CR; Russo M; Alvarez JM; D'Império Lima MR
Immunology; 2005 Apr; 114(4):499-506. PubMed ID: 15804287
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production.
Macatonia SE; Doherty TM; Knight SC; O'Garra A
J Immunol; 1993 May; 150(9):3755-65. PubMed ID: 8097224
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
17. IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo.
Roberts JM; Yang J; Ronchese F
Int Immunol; 2004 Oct; 16(10):1451-8. PubMed ID: 15326095
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
[TBL] [Abstract][Full Text] [Related]
19. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS
Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206
[TBL] [Abstract][Full Text] [Related]
20. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo.
Oldenhove G; de Heusch M; Urbain-Vansanten G; Urbain J; Maliszewski C; Leo O; Moser M
J Exp Med; 2003 Jul; 198(2):259-66. PubMed ID: 12874259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
